Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0AHSMK
ADC Name
6B6-TG6-vc0101
Synonyms
6B6 TG6 vc0101
   Click to Show/Hide
Organization
Pfizer Inc.
Drug Status
Investigative
Indication
In total 4 Indication(s)
Adult T acute lymphoblastic leukemia [ICD11:2A90]
Investigative
Burkitt lymphoma [ICD11:2A85]
Investigative
Mature T-cell lymphoma [ICD11:2A90] [ICD11:2A90]
Investigative
Plasma cell myeloma [ICD11: 2A83]
Investigative
Drug-to-Antibody Ratio
2
Antibody Name
6B6-TG6
  Antibody Info 
Antigen Name
C-X-C chemokine receptor type 4 (CXCR4)
  Antigen Info 
Payload Name
Auristatin 0101
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 67.9
%
CVCL_0597
Burkitt lymphoma
Tumor Growth Inhibition value (TGI) 
≈ 85.7
%
CVCL_0597
Burkitt lymphoma
Tumor Growth Inhibition value (TGI) 
≈ 99
%
CVCL_0597
Burkitt lymphoma
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.06
nM
CVCL_0013
Adult T acute lymphoblastic leukemia
Half Maximal Inhibitory Concentration (IC50) 
0.07
nM
CVCL_2124
Plasma cell myeloma
Half Maximal Inhibitory Concentration (IC50) 
0.07
nM
CVCL_1820
T acute lymphoblastic leukemia
Half Maximal Inhibitory Concentration (IC50) 
0.25
nM
CVCL_0014
Plasma cell myeloma
Half Maximal Inhibitory Concentration (IC50) 
1.56
nM
CVCL_8792
Plasma cell myeloma
Half Maximal Inhibitory Concentration (IC50) 
2
nM
CVCL_0597
Burkitt lymphoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 67.90% (Day 21) Positive CXCR4 expression (CXCR4+++/++)
Method Description
Mice were treated with a single intravenous dose of the ADCs at 1.5 mg/kg.
In Vivo Model Ramos CDX model
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 85.70% (Day 21) Positive CXCR4 expression (CXCR4+++/++)
Method Description
Mice were treated with a single intravenous dose of the ADCs at 3 mg/kg.
In Vivo Model Ramos CDX model
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 99.00% (Day 21) Positive CXCR4 expression (CXCR4+++/++)
Method Description
Mice were treated with a single intravenous dose of the ADCs at 6 mg/kg.
In Vivo Model Ramos CDX model
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.06 nM Positive CXCR4 expression (CXCR4+++/++)
Method Description
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model Adult T acute lymphoblastic leukemia MOLT-4 cells CVCL_0013
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.07 nM Positive CXCR4 expression (CXCR4+++/++)
Method Description
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model Plasma cell myeloma MOLP-8 cells CVCL_2124
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.07 nM Positive CXCR4 expression (CXCR4+++/++)
Method Description
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model T acute lymphoblastic leukemia HPB-ALL cells CVCL_1820
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.25 nM Positive CXCR4 expression (CXCR4+++/++)
Method Description
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model Plasma cell myeloma RPMI-8226 cells CVCL_0014
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.56 nM Positive CXCR4 expression (CXCR4+++/++)
Method Description
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model Plasma cell myeloma MM1.S cells CVCL_8792
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 2.00 nM Positive CXCR4 expression (CXCR4+++/++)
Method Description
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
References
Ref 1 Anti-cxcr4 antibodies and antibody-drug conjugates.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.